Ambio is a specialty pharmaceutical company developing biosimilar, bioequivalent, and other complex generic drugs. Ambio has built a robust pipeline, executed partnerships with leading pharmaceutical companies, and established proprietary know-how and technological advances in peptide drug development and manufacturing. Starting in 2024, Ambio’s advanced pipeline will deliver commercial launches of several biosimilar drugs targeting blockbuster indications over the next few years. Furthermore, we are developing more complex drugs biosimilar to existing biologics and peptide drugs in the therapeutic areas of diabetes, obesity, and beyond.